Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel strategies for patients with chronic myeloproliferative disorders.

Current opinion in hematology - 1 Mar 2009

Barosi Giovanni, Rosti Vittorio

Abstract excerpt

PURPOSE OF REVIEW: This review focuses on new strategies for unmet clinical needs and on new targeted therapies in classical Philadelphia-negative myeloproliferative neoplasms. RECENT FINDINGS: Meta-analyses in essential thrombocythemia documented Janus kinase 2 (JAK2) V617F as being associated with increased risk of thrombosis. New studies reinforced the evidence of leukocytosis as an independent risk factor for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon alpha-2
Share to Janus Kinase 2
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Quinolones

Share to Thalidomide

Source

Open in PubMed Open full text

Identifiers

PMID: 19468275
DOI: 10.1097/MOH.0b013e3283257a9e
PMCID: PMC6368353

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel strategies for patients with chronic myeloproliferative disorders.PMID 19468275Read ↗

Current treatment concepts of Philadelphia-negative MPN.Semantic proximity Read ↗

Current approaches to challenging scenarios in myeloproliferative neoplasms.Semantic proximity Read ↗

[Treatment of myeloproliferative neoplasms other than chronic leukemia].Semantic proximity Read ↗

Austrian recommendations for the management of essential thrombocythemia.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.Semantic proximity Read ↗

Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.Semantic proximity Read ↗

[Recent findings and advances in treatment of myeloproliferative neoplasms].Semantic proximity Read ↗

Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.Semantic proximity Read ↗

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.Semantic proximity Read ↗

Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.